AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16877461 — intervention group
Group type: COMPARATOR
Intervention: Traditional footwear design (control group)
Number of subjects: 80
Study 15875154 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 10, 20, 40 mg
Number of subjects: 27
Study 15875154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 12519867 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenoxolone (100 mg every 8 h, orally, for 7 d)
Number of subjects: 12
Study 12519867 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenoxolone
Number of subjects: 12
Study 12519867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10657829 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion guidelines modified in April 1989, September 1991, and January 1995
Number of subjects: 256
Study 8882210 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% NaCl (HS)
Number of subjects: 52
Study 8882210 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl (IS)
Number of subjects: 52
Study 1677012 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine therapy
Number of subjects: 14
Study 6626483 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy
Number of subjects: 0
Study 6626483 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy + medication
Number of subjects: 0
Study 6626483 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 0
Study 31928076 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP (N-terminal Pro-B-type natriuretic peptide)
Number of subjects: 4147
Study 31928076 — intervention group
Group type: EXPERIMENTAL
Intervention: uPA (urokinase-type plasminogen activator)
Number of subjects: 4147
Study 31928076 — intervention group
Group type: EXPERIMENTAL
Intervention: ADM (adrenomedullin)
Number of subjects: 4147
Study 31928076 — intervention group
Group type: EXPERIMENTAL
Intervention: IL (interleukin) 16
Number of subjects: 4147
Study 31928076 — intervention group
Group type: EXPERIMENTAL
Intervention: cFn (cellular fibronectin)
Number of subjects: 4147
Study 31928076 — intervention group
Group type: EXPERIMENTAL
Intervention: IGFBP3 (insulin-like growth factor-binding protein 3)
Number of subjects: 4147
Study 30594347 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise training (3 sessions per week for 6 months)
Number of subjects: 40
Study 30594347 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study 30594347 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise training
Number of subjects: 40
Study 30594347 — intervention group
Group type: COMPARATOR
Intervention: Home-based exercise training and Usual care
Number of subjects: 40
Study 28397334 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led education intervention
Number of subjects: 118
Study 28397334 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led education plus ACT intervention
Number of subjects: 118
Study 28397334 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 118
Study 26978049 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoten children (1 tablet 3 times a day for 12 weeks)
Number of subjects: 98
Study 26978049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 24199581 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver-soothing and blood-activating decoction combined with acupuncture
Number of subjects: 63
Study 24199581 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine hydrochloride
Number of subjects: 63
Study 21095141 — intervention group
Group type: EXPERIMENTAL
Intervention: Colour-Doppler ultrasound (CDUS)
Number of subjects: 108
Study 21095141 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasonography (CEUS)
Number of subjects: 108
Study 21095141 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography angiography (CTA)
Number of subjects: 108
Study 21095141 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance angiography (MRA)
Number of subjects: 108
Study 18946662 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion
Number of subjects: 32
Study 18946662 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 32
Study 17689326 — intervention group
Group type: EXPERIMENTAL
Intervention: Potential interventions
Number of subjects: 0
Study 17689326 — intervention group
Group type: EXPERIMENTAL
Intervention: Plausible interventions
Number of subjects: 0
Study 17689326 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional interventions
Number of subjects: 0
Study 17689326 — intervention group
Group type: EXPERIMENTAL
Intervention: Efficacious interventions
Number of subjects: 0
Study 14751003 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa (n = 16)
Number of subjects: 39
Study 14751003 — intervention group
Group type: COMPARATOR
Intervention: placebo (n = 24)
Number of subjects: 39
Study 11387585 — intervention group
Group type: EXPERIMENTAL
Intervention: Bon Saint Côme device (DG)
Number of subjects: 20
Study 11387585 — intervention group
Group type: COMPARATOR
Intervention: Conventional neurorehabilitation (CG)
Number of subjects: 20
Study 9463203 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ml of 2% mepivacaine and 1 ml (30 mg) of ketorolac
Number of subjects: 72
Study 9463203 — intervention group
Group type: COMPARATOR
Intervention: 5 ml of 2% mepivacaine and 1 ml of saline solution
Number of subjects: 72
Study 9463203 — intervention group
Group type: COMPARATOR
Intervention: 5 ml of 2% mepivacaine and 1 ml of saline solution plus 30 mg of ketorolac intravenously
Number of subjects: 72
Study 8485325 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal splenorenal shunt (DSRS)
Number of subjects: 10
Study 8485325 — intervention group
Group type: COMPARATOR
Intervention: Injection sclerotherapy of esophageal varices (Control)
Number of subjects: 10
Study 3446537 — intervention group
Group type: EXPERIMENTAL
Intervention: Day case strabismus surgery without post-operative topical medication
Number of subjects: 0
Study 3446537 — intervention group
Group type: COMPARATOR
Intervention: Overnight stay with topical antibiotic and anti-inflammatory therapy for 14 days
Number of subjects: 0
Study 30630783 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human endo‐statin combined with carboplatin and etoposide (CE regimen)
Number of subjects: 72
Study 30630783 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin and etoposide
Number of subjects: 72
Study 27721170 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic pelvic trainer training (Group A)
Number of subjects: 26
Study 27721170 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic pelvic trainer training (Group B)
Number of subjects: 26
Study 27721170 — intervention group
Group type: COMPARATOR
Intervention: No training (Group A between T2 and T3)
Number of subjects: 26
Study 27721170 — intervention group
Group type: COMPARATOR
Intervention: No training (Group B before T3)
Number of subjects: 26
Study 24508516 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous enteral nutrition (CEN)
Number of subjects: 30
Study 24508516 — intervention group
Group type: COMPARATOR
Intervention: Bolus enteral nutrition (BEN)
Number of subjects: 30
Study 22929730 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dexmedetomidine (target = 0.15 ng/ml plasma)
Number of subjects: 48
Study 22929730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 20691128 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea
Number of subjects: 9
Study 20691128 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee
Number of subjects: 9
Study 20691128 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee and Green tea
Number of subjects: 9
Study 18362507 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone therapy
Number of subjects: 20
Study 18362507 — intervention group
Group type: COMPARATOR
Intervention: Untreated non-GHD short children (control)
Number of subjects: 20
Study 17190940 — intervention group
Group type: EXPERIMENTAL
Intervention: MCI-single domain
Number of subjects: 980
Study 17190940 — intervention group
Group type: EXPERIMENTAL
Intervention: MCI-multiple domains
Number of subjects: 980
Study 17190940 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonamnestic MCI
Number of subjects: 980
Study 17190940 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnestic MCI
Number of subjects: 980
Study 17190940 — intervention group
Group type: EXPERIMENTAL
Intervention: MCI modified, 1.0 SD criteria
Number of subjects: 980
Study 17190940 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonamnestic MCI-multiple domains
Number of subjects: 980
Study 17190940 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer disease (AD)
Number of subjects: 980
Study 14520131 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (400 mg qid)
Number of subjects: 61
Study 14520131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 11105733 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal and over-the-counter antidepressants
Number of subjects: 0
Study 11105733 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins and amino acids for depression
Number of subjects: 0
Study 8957975 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing CPB flow rates from 2.4 to 3.0 litre min‐1 m‐2
Number of subjects: 12
Study 8957975 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine 6 micrograms kg‐1 min‐1
Number of subjects: 12
Study 1558003 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment for ISH
Number of subjects: 0
Study 3891285 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered amphotericin B infusions (1 micron filter)
Number of subjects: 15
Study 3891285 — intervention group
Group type: COMPARATOR
Intervention: Unfiltered amphotericin B infusions
Number of subjects: 15
Study 31949235 — intervention group
Group type: EXPERIMENTAL
Intervention: Google Earth elevation data extraction and correction regression model (CRM)
Number of subjects: 15086
Study 31949235 — intervention group
Group type: COMPARATOR
Intervention: Google Earth elevation data extraction
Number of subjects: 15086
Study 29164960 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 0.05% cream plus emollient (Group A)
Number of subjects: 123
Study 29164960 — intervention group
Group type: COMPARATOR
Intervention: Emollient alone (Group B)
Number of subjects: 123
Study 27470152 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin 2 g intravenously 30 minutes prior to the procedure (n = 91)
Number of subjects: 180
Study 26133206 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender and sleep hygiene
Number of subjects: 79
Study 26133206 — intervention group
Group type: COMPARATOR
Intervention: Sleep hygiene alone
Number of subjects: 79
Study 23966329 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy eating and physical activity intervention
Number of subjects: 542
Study 23966329 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 542
Study 20371663 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c level of 6.1%
Number of subjects: 1972
Study 20371663 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c level of 6.5% (+/‐2 SD)
Number of subjects: 1972
Study 20371663 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c level of 7% (+/‐2.7 SD)
Number of subjects: 1972
Study 20371663 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c level of 6.5%
Number of subjects: 1972
Study 20371663 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c level of 7%
Number of subjects: 1972
Study 18680228 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg daily for 3 years)
Number of subjects: 137
Study 18680228 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matched identical placebo for 3 years)
Number of subjects: 137
Study 15897687 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% diclofenac-Na Emulgel applied 6 and 10 hours after irradiation
Number of subjects: 0
Study 15897687 — intervention group
Group type: EXPERIMENTAL
Intervention: Single application of 0.1% diclofenac-Na Emulgel
Number of subjects: 0
Study 15897687 — intervention group
Group type: EXPERIMENTAL
Intervention: Second application of 0.1% diclofenac-Na Emulgel 4 hours after the first
Number of subjects: 0
Study 15897687 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study 14559424 — intervention group
Group type: EXPERIMENTAL
Intervention: Handling time interval for lifting tasks
Number of subjects: 9
Study 14559424 — intervention group
Group type: COMPARATOR
Intervention: Handling time interval for lowering tasks
Number of subjects: 9
Study 14559424 — intervention group
Group type: EXPERIMENTAL
Intervention: Load weights (10, 15, and 20 kg)
Number of subjects: 9
Study 14559424 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranges of motion (FS, KS, SF, FK, KF, SK)
Number of subjects: 9
Study 10383544 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 11
Study 10383544 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 11
Study 8905278 — intervention group
Group type: COMPARATOR
Intervention: High dose fentanyl/midazolam anesthesia
Number of subjects: 27
Study 8905278 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracolumbar epidural blockade with high dose fentanyl/midazolam anesthesia
Number of subjects: 27
Study 1893006 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymostimulin (TP-1)
Number of subjects: 40
Study 1893006 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving thymostimulin)
Number of subjects: 40
Study 6410898 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/kg ideal body weight amino acid infusion
Number of subjects: 5
Study 6410898 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g/kg ideal body weight amino acid infusion
Number of subjects: 5
Study 31888241 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant extracts (Berberis aristata, Elaeis guineensis, Coffea canephora)
Number of subjects: 49
Study 31888241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 29871849 — intervention group
Group type: EXPERIMENTAL
Intervention: SBRT + CGA
Number of subjects: 51
Study 29871849 — intervention group
Group type: COMPARATOR
Intervention: SBRT - CGA
Number of subjects: 51
Study 27271320 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature at 20°C
Number of subjects: 4
Study 27271320 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature at 25°C
Number of subjects: 4
Study 27271320 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature at 5°C
Number of subjects: 4
Study 27271320 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature at 10°C
Number of subjects: 4
Study 27271320 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature at 15°C
Number of subjects: 4
Study 24107112 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg naltrexone (high-dosage group)
Number of subjects: 36
Study 24107112 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg naltrexone (low-dosage group)
Number of subjects: 36
Study 24107112 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable depot naltrexone (400 mg)
Number of subjects: 36
Study 24107112 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in both panels)
Number of subjects: 36
Study 22991696 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepotastine besilate ophthalmic solution 1.5% (BBOS)
Number of subjects: 157
Study 22991696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 20622475 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment (at least 5 days before operation)
Number of subjects: 584
Study 20622475 — intervention group
Group type: COMPARATOR
Intervention: No statin treatment
Number of subjects: 584
Study 17182810 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc plus IFA
Number of subjects: 94359
Study 17182810 — intervention group
Group type: COMPARATOR
Intervention: IFA alone
Number of subjects: 94359
Study 15138760 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.3 mg/kg acute dose
Number of subjects: 75
Study 15138760 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.6 mg/kg acute dose
Number of subjects: 75
Study 15138760 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Methylphenidate administration
Number of subjects: 75
Study 15138760 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy boys)
Number of subjects: 75
Study 12243813 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin (OXA) 25 mg/m²/day in 30-min infusions, bolus leucovorin (LV) 20 mg/m²/day, bolus 5-FU 375 mg/m²/day, given on 4 days during Weeks 1 and 5 of radiotherapy (50.4 Gy). A single OXA dose (50 mg/m²) was given on the third week of radiotherapy.
Number of subjects: 22
Study 11165426 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with exposure therapy in a group context
Number of subjects: 6
Study 11165426 — intervention group
Group type: COMPARATOR
Intervention: Comparison treatment avoiding trauma focus
Number of subjects: 6
Study 9279199 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin infusion
Number of subjects: 23
Study 9279199 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 degrees head-up tilt
Number of subjects: 23
Study 8235009 — intervention group
Group type: EXPERIMENTAL
Intervention: 12‐14 weeks unsupervised physical training at home
Number of subjects: 118
Study 8235009 — intervention group
Group type: COMPARATOR
Intervention: Control group (informally encouraged to practice exercise)
Number of subjects: 118
Study 3551570 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler method B for measurement of atrial depressurization time
Number of subjects: 200
Study 3551570 — intervention group
Group type: COMPARATOR
Intervention: Doppler method A for measurement of atrial depressurization time
Number of subjects: 200
Study 3551570 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler method B
Number of subjects: 200
Study 29339313 — intervention group
Group type: EXPERIMENTAL
Intervention: androstadienone (AND)
Number of subjects: 80
Study 27214168 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended‐ABCT (5 individual CBT sessions and 7 sessions of ABCT)
Number of subjects: 59
Study 27214168 — intervention group
Group type: COMPARATOR
Intervention: ABCT (Alcohol Behavioral Couple Therapy)
Number of subjects: 59
Study 24309905 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 20-70 mg/day
Number of subjects: 143
Study 24309905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 24309905 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 143
Study 23620396 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux dialysis
Number of subjects: 704
Study 23620396 — intervention group
Group type: COMPARATOR
Intervention: Low-flux dialysis
Number of subjects: 704
Study 23620396 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux dialysis (subgroup with arteriovenous fistulas)
Number of subjects: 704
Study 23620396 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux dialysis (diabetic subjects)
Number of subjects: 704
Study 23620396 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrapure dialysate (subjects with more than 3 years of dialysis)
Number of subjects: 704
Study 23620396 — intervention group
Group type: COMPARATOR
Intervention: Ultrapure dialysate
Number of subjects: 704
Study 23620396 — intervention group
Group type: COMPARATOR
Intervention: Standard dialysate
Number of subjects: 704
Study 20384496 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of 7-valent PCV (PCV7) at ages 4 and 6 months
Number of subjects: 545
Study 20384496 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of 7-valent PCV (PCV7) at ages 2, 4, and 6 months
Number of subjects: 545
Study 20384496 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of PCV7 at age 12 months
Number of subjects: 545
Study 20384496 — intervention group
Group type: COMPARATOR
Intervention: Noncarried serotypes
Number of subjects: 545
Study 18764815 — intervention group
Group type: EXPERIMENTAL
Intervention: MM group
Number of subjects: 296
Study 18764815 — intervention group
Group type: COMPARATOR
Intervention: Fe group
Number of subjects: 296
Study 18764815 — intervention group
Group type: COMPARATOR
Intervention: IZ group
Number of subjects: 296
Study 16395845 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 44
Study 16395845 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 44
Study 16395845 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 44
Study 12971419 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A (three equal, divided doses given with meals over 10 h)
Number of subjects: 16
Study 12971419 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol B (three equal doses over 14 h)
Number of subjects: 16
Study 12971419 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol C (four equal doses over 14 h)
Number of subjects: 16
Study 12971419 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol D (six equal doses over 24 h)
Number of subjects: 16
Study 10480516 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart (0.2 U/kg)
Number of subjects: 20
Study 10480516 — intervention group
Group type: COMPARATOR
Intervention: Regular insulin (0.2 U/kg)
Number of subjects: 20
Study 8917741 — intervention group
Group type: EXPERIMENTAL
Intervention: High-saturated fat (SFA) diet
Number of subjects: 55
Study 8917741 — intervention group
Group type: COMPARATOR
Intervention: Low-saturated/high-polyunsaturated-fat (PUFA) diet
Number of subjects: 55
Study 8917741 — intervention group
Group type: EXPERIMENTAL
Intervention: ApoB SP24 allele presence
Number of subjects: 55
Study 8917741 — intervention group
Group type: EXPERIMENTAL
Intervention: LPL HindIII genotype H+ H+
Number of subjects: 55
Study 8917741 — intervention group
Group type: EXPERIMENTAL
Intervention: ApoCIII genotype CC
Number of subjects: 55
Study 1865551 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine-supplemented soft diet (40 mumol/kg per day)
Number of subjects: 18
Study 1865551 — intervention group
Group type: COMPARATOR
Intervention: Ordinary postoperative soft diet
Number of subjects: 18